



**Announcement of  
the listing in NHI Drug Price List and the Launch Date of  
THYRADIN<sup>®</sup>-S Intravenous Injection 200µg**

---

ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo, President: Takashi Yamaguchi, hereinafter "ASKA") announced that the thyroid hormone preparation "THYRADIN<sup>®</sup>-S Intravenous Injection 200µg" (generic name: Levothyroxine sodium, hereafter, "This medicine") has been listed on the National Health Insurance (NHI) Drug Price List as of April 22<sup>nd</sup> 2020 and will be launched in late June 2020.

This medicine is a drug for which ASKA received a request for development by the Ministry of Health, Labor and Welfare, as determined by the "Unapproved Medicine / Off-label Medicine Review Committee with High Medical Needs" qualifying to have a high medical need.

THYRADIN<sup>®</sup>-S Intravenous Injection 200µg already received regulatory approval for its manufacture and commercialization as a therapeutic drug for Myxoedema coma and Hypothyroidism (limited to cases in which treatment with oral levothyroxine sodium is not appropriate) by the Ministry of Health, Labor and Welfare on January 23, 2020 and has now been included on the NHI Drug Price List on April 22, 2020.

Myxoedema coma is a life-threatening disease, if appropriate treatment is not started early, but there are no intravenous injections available on the Japanese market

ASKA strives to contribute to the treatment of patients by providing this drug as a significant new option for the treatment of thyroid dysfunction.

About THYRADIN<sup>®</sup>-S Intravenous Injection 200µg

THYRADIN<sup>®</sup>-S Intravenous Injection 200µg (levothyroxine sodium) is indicated for Myxoedema coma / Hypothyroidism (limited to cases in which treatment with oral levothyroxine sodium is not appropriate). This medicine is diluted with Japanese Pharmacopoeia saline and the initial dose for adults normally, is 50 to 400µg of levothyroxine sodium given slowly administered intravenously once daily, and then the second and subsequent days dose is 50 to 100µg

once a day. In addition, a dose may be adjusted appropriately depending on the condition of the patient.

#### About ASKA

ASKA is a Japanese R&D-oriented company which aims to become a specialty pharma player. The Company is listed in the first section of the Tokyo Stock Exchange and will celebrate its 100th anniversary in 2020. Annual sales were \$425M in 2018. With a state-of-the-art manufacturing site, research and development center as well as sales offices throughout Japan with approximately 800 employees, complete dedication relating to the development and marketing of innovative medicines in Japan is assured.

The Company's therapeutic areas of focus are Women's health, Urology and disorders relating to Gastroenterology and the thyroid gland.

**ASKA Corporate Philosophy: *Contribute toward the improvement of people's health and progress in medicine through the development of innovative products***